Hepatocyte and Macrophage Interactions in Liver Disease: A Survey

Abstract

This survey paper explores the complex interplay between hepatocytes and macrophages in liver disease, focusing on their roles in inflammation and immune response. Liver diseases, particularly non-alcoholic fatty liver disease (NAFLD) and alcoholic liver disease (ALD), pose significant global health challenges due to their rising prevalence and severe outcomes like cirrhosis and hepatocellular carcinoma. Hepatocytes, the liver's primary functional cells, are active participants in the inflammatory milieu, contributing to disease progression through mechanisms such as lipid accumulation and pyroptosis. Macrophages, with their ability to polarize into pro-inflammatory (M1) and anti-inflammatory (M2) phenotypes, play a pivotal role in modulating liver inflammation and fibrosis. The survey systematically examines the signaling pathways and molecular interactions between these cells, highlighting the therapeutic potential of targeting these pathways. Therapeutic strategies discussed include modulating macrophage polarization, targeting signaling pathways like AMPK and NLRP3, and lifestyle interventions such as exercise. Emerging clinical trials focus on novel biomarkers and therapies to disrupt inflammatory cascades in liver disease. This paper underscores the importance of understanding hepatocyte-macrophage interactions to develop effective therapies, suggesting areas for future research to improve liver disease management.

1 Introduction

1.1 Significance of Liver Disease

Liver disease poses a significant global health challenge, with increasing prevalence due to both alcoholic and non-alcoholic causes. Non-alcoholic fatty liver disease (NAFLD) has emerged as the most common liver condition worldwide, significantly contributing to liver-related morbidity and mortality. NAFLD encompasses a spectrum of liver abnormalities, from simple steatosis to nonalcoholic steatohepatitis (NASH), advanced fibrosis, cirrhosis, and hepatocellular carcinoma (HCC). Its rising prevalence, primarily driven by obesity and insulin resistance, heightens the risk of end-stage liver disease and positions NASH as a leading indication for liver transplantation. Patients with advanced fibrosis linked to NAFLD face markedly higher liver-related and cardiovascular mortality rates compared to the general population, emphasizing the urgent need for improved understanding and management of this disease [1, 2]. The pathogenesis of NAFLD involves complex interactions between hepatocytes and immune cells, which drive inflammation and fibrosis, highlighting the necessity of elucidating these cellular dynamics in liver pathology.

Alcoholic liver disease (ALD) also remains a critical concern, where inflammation is central to its progression. The interplay between alcohol-induced liver injury, inflammation, and gut microbiota complicates ALD pathology, necessitating comprehensive insights into these interactions [3]. The obesity epidemic and physical inactivity exacerbate NAFLD and NASH prevalence, underscoring the importance of lifestyle interventions, such as physical exercise, to mitigate these conditions [4].



Figure 1: chapter structure

Current research focuses on the inflammasome's role in exacerbating liver inflammation and fibrosis, illustrating the need to unravel the molecular mechanisms underlying liver disease progression [5]. Furthermore, NAFLD has been identified as an independent risk factor for sepsis, underscoring the systemic implications of liver pathology. Understanding cellular interactions in liver disease is pivotal for developing targeted therapeutic strategies and alleviating the global burden of liver-related conditions.

1.2 Roles of Hepatocytes and Macrophages

Hepatocytes, the liver's primary functional cells, are crucial for maintaining metabolic homeostasis through detoxification, protein synthesis, and bile production. Their significant regenerative capacity enables them to replace damaged cells and sustain liver function post-injury [6]. In liver disease, hepatocytes transition from passive victims to active participants in the inflammatory milieu, especially in NASH, where lipid accumulation induces sublethal injury, triggering stress responses and proapoptotic pathways that contribute to inflammation and fibrosis. Hepatocyte pyroptosis further exacerbates these processes, illustrating their dual role in liver function and disease progression [7]. NAFLD exemplifies the spectrum of hepatocyte involvement, ranging from simple steatosis to advanced stages characterized by inflammation, fibrosis, and cirrhosis [2].

Macrophages play a pivotal role in liver immunology, exhibiting plasticity that allows them to polarize into pro-inflammatory (M1) and anti-inflammatory (M2) phenotypes, which are essential for modulating liver inflammation, tissue repair, and fibrosis [8]. Acting as regulatory hubs in the inflammatory response, they initiate, perpetuate, and resolve inflammation [9]. In NASH, the hepatic recruitment of monocyte-derived macrophages (MoMF) is influenced by hepatocyte lipotoxicity, although the precise mechanisms remain unclear [10]. Macrophages respond to chemokines and cytokines, such as tumor necrosis factor- (TNF), which are central to orchestrating the liver's immune response and represent potential therapeutic targets. The aryl hydrocarbon receptor (AHR) is another critical player in hepatic immune responses, with therapeutic targeting potential in liver diseases [11]. The interaction between hepatocytes and macrophages is integral to liver disease pathogenesis, particularly in NAFLD, where their interplay significantly influences disease outcomes [12]. Understanding these roles is vital for elucidating liver disease mechanisms and developing targeted therapeutic strategies [13].

1.3 Complex Interplay in Liver Inflammation

The interactions between hepatocytes and macrophages are central to the inflammatory processes underlying liver disease. Sublethal hepatocyte injury fosters a proinflammatory environment, activating aberrant signaling pathways that engage immune cells, thus illustrating the bidirectional communication between hepatocyte injury and immune responses [14]. This dynamic is particularly evident in NAFLD, where the progression from simple steatosis to NASH is driven by the complex interplay between hepatocytes and macrophages [2]. Pyroptotic cell death and inflammasome activation further contribute to this intercellular dialogue, influencing disease trajectory and highlighting hepatocytes' role in modulating immune responses [7].

Macrophages, with their ability to polarize into pro-inflammatory and anti-inflammatory phenotypes, are pivotal in orchestrating the liver's immune environment. The interactions between chemokines and macrophage behavior are crucial in shaping inflammatory responses as these cells navigate the hepatic landscape [8]. Chronic inflammation, perpetuated by these cellular interactions, drives fibrosis and the development of severe liver complications, including cirrhosis and HCC. The loss of hepatocyte regenerative capacity exacerbates these conditions, as impaired cell division contributes to the pathological manifestations of fibrosis and inflammation [6].

Understanding the complex dynamics of macrophage functions during inflammatory responses remains a significant challenge, modulated by numerous molecular and cellular interactions [9]. In NAFLD, the impact of liver dysfunction extends beyond hepatic borders, affecting systemic conditions such as sepsis and increasing patient mortality [12]. This section sets the stage for a detailed exploration of the molecular mechanisms and signaling pathways underpinning the interactions between hepatocytes and macrophages, critical for liver inflammation progression and resolution.

1.4 Structure of the Survey

This survey is systematically organized to provide a comprehensive understanding of the interactions between hepatocytes and macrophages in liver disease, focusing on their implications for therapeutic interventions. It begins with an introduction that highlights the significance of liver disease, the roles of hepatocytes and macrophages, and their complex interplay in liver inflammation and immune response, setting the stage for subsequent sections.

The second section, Background, delves into the prevalence and impact of liver diseases, such as NAFLD and ALD, discussing hepatocyte and macrophage roles in both normal and diseased states. This is followed by a Definitions and Core Concepts section, which provides essential definitions and explores macrophage biology and polarization, crucial for understanding their role in liver disease.

The fourth section, Hepatocyte and Macrophage Interactions, explores mechanisms by which these cells interact, contributing to liver inflammation and disease progression, including discussions on signaling pathways and molecular mechanisms. The fifth section focuses on Liver Inflammation and Immune Response, examining inflammation's role in liver disease, particularly the contributions of hepatocytes and macrophages to the inflammatory process and its implications for disease progression.

The survey transitions to Therapeutic Implications, discussing potential strategies targeting hepatocyte and macrophage interactions to manage liver inflammation and disease, highlighting emerging clinical trials and research directions aimed at modulating immune responses in liver disease. Finally, the Conclusion summarizes key points discussed, emphasizing the importance of understanding hepatocyte and macrophage interactions for developing effective therapies and suggesting areas for future research. This structured approach ensures a logical flow, guiding the reader through the complexities of liver disease pathology and potential therapeutic avenues.The following sections are organized as shown in Figure 1.

2 Background

2.1 Prevalence and Impact of Liver Diseases

Liver diseases, notably non-alcoholic fatty liver disease (NAFLD) and alcoholic liver disease (ALD), are escalating public health concerns due to their increasing prevalence and profound health impacts. NAFLD, characterized by excessive hepatic lipid accumulation, is the foremost cause of chronic

liver disease worldwide, closely linked to metabolic syndromes such as obesity, type 2 diabetes, and dyslipidemia, necessitating deeper investigation into its long-term effects and therapeutic approaches. The transition from NAFLD to non-alcoholic steatohepatitis (NASH) is particularly concerning, elevating risks for cirrhosis, liver-related mortality, and hepatocellular carcinoma [15]. This progression is fueled by a cycle of insulin resistance, lipotoxicity, and inflammation [16].

Chronic inflammation is central to NAFLD and ALD progression. In NAFLD, hepatocyte lipotoxicity activates inflammatory pathways, leading to liver damage and fibrosis [14]. The AMP-activated protein kinase (AMPK) pathway is crucial for lipid metabolism and inflammation in both NAFLD and alcoholic fatty liver disease (AFLD) [17]. Conversely, ALD is primarily driven by alcohol-induced liver damage, where inflammation and gut microbiota play significant roles in its pathogenesis. This inflammatory response not only results from liver damage but also exacerbates disease progression, culminating in severe fibrosis and hepatocellular carcinoma [18].

The global NAFLD burden is heightened by rising metabolic disorders and lifestyle changes, emphasizing the need for a thorough understanding of cellular interactions in liver pathology [19]. The obesity epidemic, a major factor in metabolic diseases, underscores the societal implications of insulin resistance [4]. Physical inactivity further exacerbates NAFLD and NASH severity, contributing to liver-related morbidity and mortality [20]. The challenge of non-invasively detecting liver inflammation in chronic liver disease patients, especially those with NAFLD, highlights the societal impact of liver diseases [21]. Moreover, research links NAFLD to increased septic mortality, indicating broader systemic implications [12].

As NAFLD and ALD prevalence continues to rise, understanding their epidemiology and societal impact is crucial for shaping public health strategies and clinical interventions. A comprehensive grasp of the mechanisms underlying liver inflammation and fibrosis is essential for developing targeted therapeutic strategies, potentially alleviating the societal burden of liver diseases, including chronic conditions like cirrhosis and NAFLD, which account for over 1 million deaths annually worldwide [18, 22].

2.2 Hepatocytes in Normal and Diseased States

Hepatocytes, the liver's primary parenchymal cells, are essential for metabolic homeostasis through detoxification, protein synthesis, and bile production [23]. These functions are vital for digestion and metabolic regulation, highlighting hepatocytes' importance in liver physiology. The liver's remarkable regenerative capacity, enabled by hepatocyte proliferation, allows recovery from injury and maintenance of functional integrity [6]. However, replicating the complex microenvironments necessary for optimal hepatocyte function remains a significant challenge in tissue engineering, hindering the development of bio-artificial liver systems [23].

In pathological states like NAFLD and ALD, hepatocyte functions are severely impaired. NAFLD disrupts normal hepatocyte activities, leading to inflammation and fibrosis [2]. This condition is characterized by abnormal lipid accumulation, driven by factors such as high-fat diets and ethanol consumption [17]. The transition from NAFLD to NASH is particularly concerning due to its association with liver fibrosis and increased risk of adverse outcomes, including cirrhosis and hepatocellular carcinoma.

The biological mechanisms driving these diseases involve intricate interactions among insulin resistance, lipotoxicity, and inflammation, which alter hepatocyte functions and promote disease progression. Lipotoxic signals from hepatocytes enhance monocyte-derived macrophage (MoMF) inflammation in NASH, although the precise mechanisms remain to be fully elucidated [10]. Additionally, organelle stress responses, such as endoplasmic reticulum stress and mitochondrial dysfunction, along with autophagy dysregulation and inflammatory mediator release, further compromise hepatocyte functions and exacerbate liver disease [24]. The role of the NOD-like receptor protein 3 (NLRP3) inflammasome in liver inflammation, particularly in NAFLD, complicates the disease landscape [19].

In ALD, liver damage progresses through stages, including alcoholic fatty liver disease (AFL), alcoholic steatohepatitis (ASH), and alcoholic hepatitis (AH), each reflecting increasing levels of hepatocyte dysfunction and liver injury [25]. The inflammatory and proliferative responses triggered by the isolation and culture of primary human hepatocytes (PHH) result in the down-regulation of liver-enriched transcription factors, leading to a loss of the hepatic phenotype [26]. These challenges underscore the need for a better understanding of the crosstalk between hepatocytes and immune

cells to develop effective therapeutic strategies [22]. Additionally, the reliance on animal models, which may not fully capture the complexity of human responses, highlights the necessity for more human data in current studies [3].

2.3 Macrophages and Their Role in Liver Physiology

Macrophages are crucial for liver homeostasis, demonstrating remarkable heterogeneity that allows adaptation to various physiological contexts [27]. In a healthy liver, resident macrophages, known as Kupffer cells, maintain tissue homeostasis by clearing apoptotic cells and debris, producing anti-inflammatory cytokines, and regulating immune responses, which are crucial for preventing unnecessary inflammation and maintaining liver function.

In liver disease, macrophages undergo significant changes, transitioning from homeostatic roles to active participants in inflammatory processes. In NAFLD, they are pivotal in the inflammatory response, contributing to disease progression through the release of pro-inflammatory cytokines and chemokines [2]. The infiltration and activation of monocytes, mediated by extracellular vesicles released from injured hepatocytes, exemplify the role of macrophages in perpetuating liver inflammation [14]. This dynamic interplay highlights the importance of macrophages in modulating the liver's immune environment during disease states.

Macrophages also play a critical role in tissue repair and fibrosis development, which are essential aspects of liver physiology and disease [8]. The transition from a pro-inflammatory to a reparative phenotype is crucial for resolving inflammation and promoting tissue repair. However, dysregulation of this process can lead to excessive fibrosis, contributing to the progression of chronic liver diseases.

In ALD, macrophages are central to the inflammatory processes driving liver injury. Existing research highlights the roles of various immune cells, cytokines, and mediators in liver damage, emphasizing the interplay between inflammation and liver health [28]. Additionally, macrophages in visceral adipose tissue (VAT) are implicated in mediating inflammation and insulin resistance, underscoring their critical role in the pathophysiology of obesity-related liver disease [4].

Recent advancements in imaging techniques, such as the use of radiolabeled anti-VCAM-1 nanobodies, have provided new insights into macrophages' roles in liver inflammation and their interactions with hepatocytes [21]. These technologies offer promising avenues for understanding the complex dynamics of macrophage functions in liver disease.

Moreover, the metabolic interplay between liver macrophages and hepatocytes, particularly involving TREM2, introduces a novel perspective on their coordination in liver physiology and disease [12]. The development of in silico modeling approaches has also enhanced our understanding of macrophage functions in inflammation, offering insights that could lead to improved therapeutic strategies for inflammatory diseases [9].

The role of macrophages in liver physiology is complex and multifaceted, essential for maintaining homeostasis through regulating metabolic processes, modulating immune responses, and participating in various disease mechanisms, including chronic liver inflammation and injury. These tissue-resident macrophages, originating from embryonic progenitors and replenished by blood monocytes, actively participate in organ-specific functions and systemic homeostasis, influencing both liver health and disease outcomes [27, 24]. Understanding these roles is crucial for developing targeted therapeutic strategies to manage liver diseases effectively.

In the study of liver disease, particularly non-alcoholic fatty liver disease (NAFLD), it is essential to understand the role of macrophages and their polarization within the liver microenvironment. Figure 2 illustrates the core concepts and definitions related to liver disease and macrophage polarization, highlighting the significance of NAFLD and the roles of macrophages in liver pathology. This figure categorizes key terms, macrophage origins, functions, and polarization dynamics, emphasizing their impact on disease progression and potential therapeutic strategies. By integrating these elements, we can better appreciate the complex interplay between macrophages and liver health, paving the way for innovative treatment approaches.

3 Definitions and Core Concepts

3.1 Key Terms and Definitions

Understanding liver disease requires familiarity with key terms. Non-alcoholic fatty liver disease (NAFLD) involves excessive fat deposition in hepatocytes without significant alcohol intake or other liver disease causes. It ranges from simple steatosis to non-alcoholic steatohepatitis (NASH), characterized by inflammation and fibrosis, potentially leading to cirrhosis and hepatocellular carcinoma. The increasing prevalence of NAFLD, linked to obesity and insulin resistance, poses severe health threats, including elevated liver-related and cardiovascular mortality, and is anticipated to become a primary reason for liver transplantation [1, 2].

Macrophage polarization, the process by which macrophages assume pro-inflammatory (M1) or anti-inflammatory (M2) roles based on environmental signals, is critical for understanding their involvement in liver diseases [8]. Chemokines, as signaling molecules, direct immune cell migration and activation, orchestrating the liver's inflammatory response [8]. Categorizing liver inflammation by immune cell types, including Kupffer cells, macrophages, and T lymphocytes, is vital for analyzing the immune landscape and disease progression [22]. Furthermore, androgen and estrogen receptors impact immune modulation in drug-induced liver injury (DILI), highlighting gender-specific mechanisms in liver pathology [29]. These definitions lay the groundwork for exploring cellular dynamics and therapeutic implications in liver disease.

3.2 Macrophage Biology and Polarization

Macrophages, derived from yolk sac progenitors and bone marrow monocytes, are crucial for tissue homeostasis and immune regulation [27]. In the liver, Kupffer cells, the resident macrophages, maintain immunological balance through phagocytosis and inflammation modulation.

This diverse and adaptable cell population can polarize into various functional states, traditionally categorized as pro-inflammatory (M1) and anti-inflammatory (M2). However, this binary classification is increasingly seen as simplistic, as macrophages can display a spectrum of phenotypes influenced by physiological and pathological stimuli, such as obesity and cancer [27, 8]. Polarization dynamics are crucial for liver pathology, with M1 macrophages, activated by microbial products and pro-inflammatory cytokines, generating reactive oxygen species that can clear pathogens but also cause tissue damage. In contrast, M2 macrophages are linked to tissue repair, secreting anti-inflammatory cytokines and promoting extracellular matrix deposition.

As illustrated in Figure 3, the figure highlights the key roles of macrophages in tissue homeostasis and immune regulation, their polarization into M1 and M2 states, and the implications for liver diseases such as NAFLD and ALD. The balance between M1 and M2 macrophages significantly affects liver disease outcomes. Dysregulation of this balance in NAFLD and alcoholic liver disease (ALD) can lead to chronic inflammation and fibrosis, driving disease progression. The shift from M1 to M2 phenotype is essential for resolving inflammation and restoring liver function, as it aids tissue repair and mitigates chronic injury effects [18, 30, 24, 6, 27]. Failures in this transition can result in persistent inflammation and progressive fibrosis.

Understanding the molecular signals controlling macrophage polarization in the liver is crucial for developing targeted therapies to modulate immune responses. Strategies promoting M2 polarization may reduce liver inflammation and fibrosis, highlighting macrophages' therapeutic potential in liver diseases. Continued research into macrophage biology and their interactions with hepatocytes and cytokines will further elucidate their roles in disease progression and fibrosis development [18, 24, 9].

4 Hepatocyte and Macrophage Interactions

4.1 Mechanisms of Hepatocyte-Driven Inflammation

Hepatocytes are central to liver function and disease pathogenesis, particularly in NAFLD and its progression to NASH. This transition is marked by hepatocyte-induced inflammation and fibrosis, driven by metabolic stress and lipotoxicity. The dysregulation of metabolism in NAFLD, often due to excess triglycerides and free fatty acids, initiates a cycle of insulin resistance and inflammation, exacerbating lipotoxicity and activating immune responses that further inflammation and fibrosis.

This process accelerates NAFLD progression, increasing the risk of cirrhosis and hepatocellular carcinoma [16, 2, 22].

A key inflammatory pathway in hepatocytes involves NLRP3 inflammasome activation, mediating inflammation and fibrosis through hepatic stellate cell activation. Stressed hepatocytes also upregulate VCAM-1, contributing to an inflammatory milieu [21]. Additionally, hepatocyte polyploidy and DNA damage, resulting from inhibited cell division, further exacerbate inflammation and fibrosis [6].

Hepatocytes release lipotoxic extracellular vesicles enriched with integrin 1, promoting monocyte adhesion and inflammation in NASH [10]. Moreover, the secretion of DPP4 by stressed hepatocytes contributes to inflammation in visceral adipose tissue and exacerbates insulin resistance, illustrating hepatic inflammation's systemic impact [4].

Therapeutic strategies targeting these pathways are being explored to mitigate liver disease progression. Inhibiting TNF signaling is a potential intervention due to its role in hepatocyte-driven inflammation [31]. Lifestyle interventions, such as regular exercise, have shown efficacy in reducing liver fat and improving metabolic health in NAFLD and NASH, underscoring non-pharmacological approaches' importance in liver disease management [20].

The gut microbiota's role in ALD highlights the complex interplay between hepatocytes and systemic factors, suggesting therapeutic modulation of the microbiome could enhance liver health [25]. Gender differences in DILI responses, with males showing delayed recovery and heightened inflammatory responses compared to females, emphasize the need for personalized therapeutic approaches [29].

Understanding hepatocyte-driven inflammation mechanisms is crucial for developing targeted therapies to mitigate liver disease progression, as evidenced by in silico models predicting macrophage behavior in inflammatory contexts [9].

4.2 Macrophage Polarization and Function

Macrophages, with their adaptability, play a crucial role in maintaining tissue homeostasis and modulating immune responses [27]. Their polarization into M1 and M2 phenotypes is essential for their roles in liver inflammation and the broader immune response [8]. As depicted in Figure 4, this figure illustrates the hierarchical structure of macrophage polarization and function, focusing on their roles in tissue homeostasis and immune modulation, as well as the distinction between M1 and M2 macrophage phenotypes and their impact on liver diseases such as NAFLD and ALD.

M1 macrophages, induced by pro-inflammatory cytokines and microbial products, exhibit a glycolytic metabolic profile that supports reactive oxygen species and pro-inflammatory cytokine production, contributing to pathogen clearance and tissue damage [30]. In contrast, M2 macrophages, activated by anti-inflammatory cytokines, rely on oxidative phosphorylation and fatty acid oxidation, facilitating tissue repair, fibrosis resolution, and anti-inflammatory mediator production [30].

Macrophage polarization dynamics allow these cells to modulate their functions in response to the hepatic microenvironment, significantly influencing liver inflammation's progression and resolution. In liver diseases like NAFLD and ALD, the interplay between M1 and M2 macrophages is critical in determining disease outcomes. M1 macrophages exacerbate liver inflammation and injury, while M2 macrophages promote tissue repair and anti-inflammatory processes. This balance is influenced by hepatocyte injury and the inflammatory microenvironment, highlighting macrophage polarization's importance in liver pathogenesis [25, 28, 8, 12, 14]. An imbalance favoring M1 macrophage activation can worsen inflammation and fibrosis, while a shift towards M2 polarization may aid in resolving inflammation and promoting tissue repair.

A comprehensive understanding of macrophage polarization's metabolic pathways and functional dynamics is essential for developing targeted therapeutic strategies to modulate immune responses in liver diseases, particularly inflammation-driven conditions like hepatitis and NASH. Promoting macrophage polarization towards an M2 phenotype may mitigate liver inflammation and fibrosis, offering potential therapeutic benefits for chronic liver condition patients [18, 30, 8, 10, 32].

4.3 Signaling Pathways and Immune Response

Signaling pathways governing hepatocyte-macrophage interactions are central to modulating immune responses and liver disease progression. Metabolic stress and lipotoxicity in hepatocytes activate

inflammatory pathways contributing to NASH and other liver conditions. A critical component of these pathways is the NLRP3 inflammasome, mediating inflammation and fibrosis through HSC activation [33]. The secretion of inflammatory cytokines, such as TNF and IL-6, exacerbates liver inflammation, with pathways like NFB and JNK significantly promoting hepatocellular carcinoma [34].

Macrophages, with their ability to polarize into distinct phenotypes, are essential to the liver's immune environment. The metabolic pathways governing macrophage polarization, including glycolysis and fatty acid oxidation, are crucial for their functional roles in inflammation and tissue repair. The balance between pro-inflammatory (M1) and anti-inflammatory (M2) macrophages is influenced by the hepatic microenvironment, where lipotoxicity promotes a pro-inflammatory state, exacerbating insulin resistance and liver pathology [4].

Hepatocyte-macrophage interactions are further modulated by signaling molecules such as TNF, with targeted TNF receptor inhibition presenting a potential therapeutic strategy to mitigate inflammation while promoting liver regeneration. The use of radiolabeled anti-VCAM-1 nanobodies for imaging provides insights into the liver's inflammatory status, highlighting the signaling pathways involved in hepatocyte-macrophage interactions [21].

TREM2, a receptor expressed in macrophages, plays a protective role against hepatic mitochondrial dysfunction, particularly in NAFLD-associated sepsis, underscoring macrophage signaling's importance in maintaining liver health and suggesting potential therapeutic targets [12]. Advanced modeling techniques integrating immune cell populations and cytokine interactions enhance our understanding of immune dynamics in liver diseases and transplantation scenarios [35].

Investigating the signaling pathways involved in hepatocyte-macrophage interactions reveals critical mechanisms underpinning inflammatory processes in the liver, contributing to chronic liver diseases like NAFLD and hepatitis. This exploration elucidates how hepatocyte injury and the subsequent immune response, mediated by macrophages and other immune cells, drive inflammation and fibrosis, leading to severe complications like cirrhosis and liver cancer. Understanding these interactions enhances our knowledge of liver pathophysiology and identifies potential therapeutic targets for mitigating disease progression [18, 15, 24].

5 Liver Inflammation and Immune Response

Understanding liver inflammation and the immune response is vital for grasping the pathophysiology of various liver diseases. This section delves into the mechanisms of liver inflammation, focusing on the interplay between cellular processes and immune system roles. By exploring the contributions of hepatocytes, macrophages, and environmental factors, we gain insights into liver disease progression and therapeutic targets. The subsequent subsection will specifically examine inflammation and fibrosis in liver disease, paving the way for a deeper understanding of these interconnected processes.

5.1 Inflammation and Fibrosis in Liver Disease

Inflammation and fibrosis are central to the progression of liver diseases like NAFLD and NASH, involving complex cellular and molecular mechanisms that exacerbate pathology. As illustrated in Figure 5, which depicts the hierarchical structure of key concepts related to inflammation and fibrosis in liver disease, these processes are intricately linked through various cellular mechanisms, molecular pathways, and therapeutic insights. Hepatocytes play a pivotal role, with MyD88 signaling linking innate immunity to metabolic changes in conditions such as type 2 diabetes and NASH [36]. This highlights hepatocyte-mediated inflammatory pathways in driving fibrosis. Macrophage polarization significantly influences inflammation and fibrosis, with M1 macrophages promoting and M2 macrophages resolving these processes [8]. Their plasticity allows adaptation to the hepatic microenvironment, modulating immune responses and influencing disease trajectories.

Hepatocyte division is crucial for liver homeostasis, and its inhibition can drive inflammation and fibrosis [6]. The aryl hydrocarbon receptor (AHR) is a key immune homeostasis regulator, promoting tolerance and preventing excessive inflammation [11]. Modulating AHR signaling presents a therapeutic avenue for managing liver inflammation and fibrosis. Environmental exposures also contribute to liver disease pathogenesis, with mechanisms linking these exposures to toxicant-associated steatohepatitis (TASH) identified [3].

Despite achieving sustained virologic response (SVR), many patients continue experiencing hepatic inflammation, with male gender and advanced liver disease as strong predictors [37]. Ongoing inflammation can exacerbate fibrosis, necessitating continued monitoring and intervention. The reliance on invasive diagnostics and the lack of universally effective treatments underscore the need for improved strategies [38]. Advances in tissue engineering, such as developing physiologically relevant hepatocyte aggregates, offer promising insights into liver disease mechanisms [23].

5.2 Inflammation in Alcoholic and Non-Alcoholic Liver Disease

Inflammatory processes in ALD and NAFLD share commonalities and exhibit distinct differences, reflecting underlying etiological factors. Both conditions feature chronic liver inflammation, crucial for progression to severe states like NASH, fibrosis, and cirrhosis. In NAFLD, inflammation is driven by lipotoxicity from hepatocyte injury, activating immune cells and leading to fibrosis. Kupffer cells and macrophages interact with hepatic stellate cells to promote fibrogenesis, emphasizing the complex interplay between inflammation and liver damage [14, 22]. Metabolic dysregulation, including insulin resistance and lipotoxicity, triggers pro-inflammatory cytokine release, perpetuating inflammation and fibrosis [19]. Oxidative stress and mitochondrial dysfunction exacerbate hepatocyte injury and inflammation [24].

In ALD, alcohol-induced liver injury disrupts gut barrier function and alters microbiota, increasing endotoxin levels and activating Kupffer cells [28]. This activation produces pro-inflammatory cytokines like TNF and IL-1, contributing to liver injury [18]. Alcohol metabolism generates reactive oxygen species (ROS), exacerbating oxidative stress and inflammation [25]. Both ALD and NAFLD share pathways like NFB and JNK activation, central to inflammatory mediator production and fibrosis promotion [34]. Macrophage recruitment and activation sustain inflammation in both conditions [8], with M1 and M2 polarization influencing progression and resolution [8].

Therapeutic strategies targeting shared pathways hold promise for managing ALD and NAFLD. Research focuses on interventions targeting macrophage polarization, mitigating oxidative stress, and restoring gut barrier integrity to reduce inflammation and slow progression. By modulating immune responses and addressing inflammatory mechanisms, these approaches may offer new therapeutic avenues to improve liver health and prevent complications like fibrosis and hepatocellular carcinoma [18, 28, 8, 24, 10]. Understanding the similarities and differences in ALD and NAFLD inflammation is crucial for developing effective therapies tailored to each condition's pathophysiology.

5.3 Lipotoxicity and Inflammation

Lipotoxicity is a critical factor in the pathogenesis of liver diseases such as NAFLD and NASH, where excess lipid accumulation in hepatocytes leads to cellular stress and inflammation. Metabolic overload results in lipotoxicity, characterized by toxic lipid species that trigger inflammatory signaling pathways and cellular injury, central to the progression from simple steatosis to NASH, where inflammation and fibrosis become prominent [14].

Lipotoxicity induces inflammation through several key pathways. The NLRP3 inflammasome is activated in response to lipotoxic stress, leading to pro-inflammatory cytokine production, such as IL-1, which perpetuates liver inflammation [19]. Additionally, lipotoxicity disrupts mitochondrial function and promotes oxidative stress, exacerbating inflammatory responses in hepatocytes [24].

Macrophage polarization significantly influences the inflammatory response to lipotoxicity. The release of lipotoxic signals from stressed hepatocytes recruits and activates macrophages, which can polarize into M1 phenotypes, amplifying inflammation [8]. This polarization is influenced by the hepatic microenvironment, where lipotoxicity fosters a pro-inflammatory state that contributes to liver disease progression.

Systemic implications of lipotoxicity are evident in elevated alanine aminotransferase (ALT) levels observed in patients post-SVR, particularly those treated with interferon (IFN)-based therapies, suggesting lingering effects on liver inflammation even after viral clearance [37].

Therapeutic strategies aimed at mitigating lipotoxicity and its associated inflammatory responses are under investigation, focusing on modulating lipid metabolism, reducing oxidative stress, and promoting macrophage polarization towards M2 phenotypes. This approach recognizes the complex role of macrophages in inflammatory conditions, where their plasticity allows diverse functional

outcomes based on environmental cues, and highlights the importance of metabolic pathways that differentiate M1 and M2 macrophages, crucial in managing diseases like NASH and ALD. By targeting these mechanisms, researchers aim to develop effective treatments addressing chronic inflammation's underlying causes and their effects on tissue health [18, 30, 28, 8, 10]. These strategies aim to mitigate liver inflammation and prevent progression to severe liver conditions, emphasizing the importance of addressing lipotoxicity in liver disease management.

6 Therapeutic Implications

Understanding the dynamic interactions between hepatocytes and macrophages is essential for advancing therapeutic strategies in liver diseases, specifically NAFLD and NASH. This section examines emerging therapeutic targets and strategies, emphasizing interventions that address both inflammatory and metabolic components to improve patient outcomes.

6.1 Therapeutic Targets and Strategies

The intricate interactions between hepatocytes and macrophages in NAFLD and NASH offer significant therapeutic potential. Modulating pathways such as MyD88 in hepatocytes, which links innate immunity to metabolic shifts, could effectively address immune and metabolic dysregulation [36]. Macrophage polarization, pivotal in liver inflammation, is a promising intervention target; promoting an anti-inflammatory phenotype through metabolic pathway regulation can reduce liver damage and enhance tissue repair [30, 39]. Targeting chemokine receptors further modulates macrophage activity and inflammatory responses [8].

The AMPK signaling pathway is a promising target for fatty liver disease therapies, as it regulates lipid metabolism and inflammation, offering dual benefits [17]. Additionally, the selective NLRP3 inhibitor MCC950 has shown potential in reducing liver inflammation and fibrosis [19]. Lifestyle changes, especially physical exercise, reduce hepatic fat and improve metabolic health, while interventions like prebiotics and probiotics modulate liver inflammation [25].

In targeted therapies, TNF receptor inhibition offers specificity and reduced side effects compared to broader anti-TNF therapies [31]. Advanced imaging techniques for early inflammation detection could enhance NAFLD management [21]. Future research should focus on post-SVR inflammation implications and gender-specific therapeutic strategies [37, 29].

Emerging research suggests miR-122 mimics as potential therapies for reversing inflammation and fibrosis in NAFLD [40], while TREM2 emerges as a target for improving NAFLD-associated sepsis outcomes [12]. Identifying novel inflammatory mediators is crucial for developing effective liver disease management strategies [15]. The development of therapies targeting hepatocyte-macrophage interactions, integrating pharmacological and lifestyle interventions, holds promise for improving patient outcomes. Utilizing in silico models for dynamic macrophage behavior predictions could guide future therapeutic strategies [9].

Figure 6 illustrates the therapeutic targets and strategies for NAFLD and NASH, focusing on hepatocyte-macrophage interactions, key signaling pathways, and emerging therapies. This visual representation complements the discussion by providing a clear overview of the complex relationships and potential intervention points in the management of these liver diseases.

6.2 Emerging Clinical Trials and Research Directions

Recent advancements in liver disease understanding, including NAFLD and ALD, have spurred innovative clinical trials for targeted therapies. In NAFLD, emphasis is on non-invasive biomarkers and therapies disrupting NASH's inflammatory cascade [14]. The extension of metabolic inhibitors from oncology to liver diseases introduces new treatment paradigms [30]. Future research should focus on novel therapeutic targets and lifestyle interventions' long-term benefits [2].

AMPK activation is a promising therapeutic target, with ongoing studies on AMPK activators' mechanisms and clinical efficacy [17]. The NLRP3 inhibitor MCC950 is being optimized for therapeutic outcomes in NAFLD [19]. In ALD, trials are assessing anti-inflammatory treatments targeting the gut microbiome and cytokines [28]. The gut-liver axis remains crucial in liver disease pathogenesis,

with microbiota-targeted therapies being explored [25]. Future research should elucidate immune cell interactions in liver inflammation and fibrosis and investigate new therapeutic targets [22].

Macrophage plasticity in metabolic and inflammatory diseases presents a promising research frontier, with efforts to clarify polarization mechanisms and therapeutic implications [27]. Future research should refine models and integrate experimental data to enhance predictive power and clinical applicability [9].

Investigating TREM2's molecular pathways and influence on macrophage function is critical, with potential therapeutic strategies targeting metabolic dysfunction in NAFLD patients [12]. Optimizing receptor-specific therapies and conducting clinical trials to assess efficacy in humans, possibly with other immunomodulatory agents, is a key focus [31].

Exercise is a fundamental lifestyle intervention, necessitating large-scale studies to clarify its liver health benefits and identify effective regimens for diverse populations [20]. Imaging techniques like 99mTc-cAbVCAM1-5 SPECT are being validated in trials to track liver disease progression [21].

Developing combination therapies targeting multiple inflammatory pathways represents a promising research direction, aiming to enhance therapeutic efficacy in liver diseases [32]. The therapeutic potential of miR-122 mimics aligns with emerging clinical trials focused on liver disease [40]. These trials and research directions offer more effective and personalized therapeutic options for liver disease patients. Future research should focus on fitting models to clinical data, exploring additional immune cell types, and validating predictions through experimental studies [35].

7 Conclusion

The intricate dynamics between hepatocytes and macrophages are central to both the pathogenesis and potential treatment strategies for liver diseases. Understanding the dual role of inflammation in causing liver damage while also facilitating tissue regeneration is essential for developing comprehensive therapeutic approaches. Hepatocyte pyroptosis is identified as a significant contributor to liver injury and fibrosis, with inflammasome activation intensifying the inflammatory milieu. Targeting the inflammasome in liver inflammation presents a complex challenge that necessitates precise therapeutic interventions. Current treatment options remain inadequate, highlighting the necessity for continued research to transform these mechanistic insights into targeted therapies. Selecting appropriate models that align with specific research goals and data availability is critical for advancing our understanding of liver diseases. A thorough comprehension of the complex interactions between hepatocytes and macrophages is imperative for crafting effective treatments, ultimately improving patient outcomes in the management of liver diseases.

References

[1] Brandon J Perumpail, Muhammad Ali Khan, Eric R Yoo, George Cholankeril, Donghee Kim, and Aijaz Ahmed. Clinical epidemiology and disease burden of nonalcoholic fatty liver disease. *World journal of gastroenterology*, 23(47):8263, 2017.

[2] Mark Benedict and Xuchen Zhang. Non-alcoholic fatty liver disease: An expanded review. *World journal of hepatology*, 9(16):715, 2017.

[3] Banrida Wahlang, Jian Jin, Juliane I Beier, Josiah E Hardesty, Erica F Daly, Regina D Schnegelberger, K Cameron Falkner, Russell A Prough, Irina A Kirpich, and Matthew C Cave. Mechanisms of environmental contributions to fatty liver disease. *Current environmental health reports*, 6:80–94, 2019.

[4] Devram S Ghorpade, Lale Ozcan, Ze Zheng, Sarah M Nicoloro, Yuefei Shen, Emily Chen, Matthias Blüher, Michael P Czech, and Ira Tabas. Hepatocyte-secreted dpp4 in obesity promotes adipose inflammation and insulin resistance. *Nature*, 555(7698):673–677, 2018.

[5] Kim HH Liss and Brian N Finck. Ppars and nonalcoholic fatty liver disease. *Biochimie*, 136:65–74, 2017.

[6] Matthew R Dewhurst, Jin Rong Ow, Gözde Zafer, Noémi KM van Hul, Heike Wollmann, Xavier Bisteau, David Brough, Hyungwon Choi, and Philipp Kaldis. Loss of hepatocyte cell division leads to liver inflammation and fibrosis. *PLoS genetics*, 16(11):e1009084, 2020.

[7] Susanne Gaul, Aleksandra Leszczynska, Fernando Alegre, Benedikt Kaufmann, Casey D Johnson, Leon A Adams, Alexander Wree, Georg Damm, Daniel Seehofer, Carolina J Calvente, et al. Hepatocyte pyroptosis and release of inflammasome particles induce stellate cell activation and liver fibrosis. *Journal of hepatology*, 74(1):156–167, 2021.

[8] Pieter Ruytinx, Paul Proost, Jo Van Damme, and Sofie Struyf. Chemokine-induced macrophage polarization in inflammatory conditions. *Frontiers in immunology*, 9:1930, 2018.

[9] Peter Ghazal, Steven Watterson, Kevin Robertson, and David C Kluth. The in silico macrophage: toward a better understanding of inflammatory disease, 2011.

[10] Qianqian Guo, Kunimaro Furuta, Fabrice Lucien, Luz Helena Gutierrez Sanchez, Petra Hirsova, Anuradha Krishnan, Ayano Kabashima, Kevin D Pavelko, Benjamin Madden, Husam Alhuwaish, et al. Integrin β1-enriched extracellular vesicles mediate monocyte adhesion and promote liver inflammation in murine nash. *Journal of hepatology*, 71(6):1193–1205, 2019.

[11] Antonella Carambia and Fenja Amrei Schuran. The aryl hydrocarbon receptor in liver inflammation. In *Seminars in Immunopathology*, volume 43, pages 563–575. Springer, 2021.

[12] Jinchao Hou, Jue Zhang, Ping Cui, Yingyue Zhou, Can Liu, Xiaoliang Wu, Yun Ji, Sicong Wang, Baoli Cheng, Hui Ye, et al. Trem2 sustains macrophage-hepatocyte metabolic coordination in nonalcoholic fatty liver disease and sepsis. *The Journal of clinical investigation*, 131(4), 2021.

[13] Cordula Reisch, Sandra Nickel, and Hans-Michael Tautenhahn. Building up a model family for inflammations, 2023.

[14] Samar H Ibrahim, Petra Hirsova, and Gregory J Gores. Non-alcoholic steatohepatitis pathogenesis: sublethal hepatocyte injury as a driver of liver inflammation. *Gut*, 67(5):963–972, 2018.

[15] Linda Hammerich and Frank Tacke. Hepatic inflammatory responses in liver fibrosis. *Nature Reviews Gastroenterology & Hepatology*, 20(10):633–646, 2023.

[16] Zhonge Chen, Rong Yu, Ying Xiong, Fangteng Du, and Shuishan Zhu. A vicious circle between insulin resistance and inflammation in nonalcoholic fatty liver disease. *Lipids in health and disease*, 16:1–9, 2017.

[17] Chunqiu Fang, Jianheng Pan, Ning Qu, Yuting Lei, Jiajun Han, Jingzhou Zhang, and Dong Han. The ampk pathway in fatty liver disease. *Frontiers in Physiology*, 13:970292, 2022.

[18] José A Del Campo, Paloma Gallego, and Lourdes Grande. Role of inflammatory response in liver diseases: Therapeutic strategies. *World journal of hepatology*, 10(1):1, 2018.

[19] Auvro R Mridha, Alexander Wree, Avril AB Robertson, Matthew M Yeh, Casey D Johnson, Derrick M Van Rooyen, Fahrettin Haczeyni, Narci C-H Teoh, Christopher Savard, George N Ioannou, et al. Nlrp3 inflammasome blockade reduces liver inflammation and fibrosis in experimental nash in mice. *Journal of hepatology*, 66(5):1037–1046, 2017.

[20] Dirk J Van Der Windt, Vikas Sud, Hongji Zhang, Allan Tsung, and Hai Huang. The effects of physical exercise on fatty liver disease. *Gene expression*, 18(2):89, 2018.

[21] Maxime Nachit, Christopher Montemagno, Romain Clerc, Mitra Ahmadi, François Briand, Sandrine Bacot, Nick Devoogdt, Cindy Serdjebi, Catherine Ghezzi, Thierry Sulpice, et al. Molecular imaging of liver inflammation using an anti-vcam-1 nanobody. *Nature communications*, 14(1):1062, 2023.

[22] Yukinori Koyama, David A Brenner, et al. Liver inflammation and fibrosis. *The Journal of clinical investigation*, 127(1):55–64, 2017.

[23] Veronica Saravia. Hepatocyte aggregates: Methods of preparation in the microgravity simulating bioreactor use in tissue engineering, 2008.

[24] Jin Gong, Wei Tu, Jingmei Liu, and Dean Tian. Hepatocytes: A key role in liver inflammation. *Frontiers in immunology*, 13:1083780, 2023.

[25] Marija Dukić, Tijana Radonjić, Igor Jovanović, Marija Zdravković, Zoran Todorović, Nemanja Kraišnik, Bojana Aranđelović, Olga Mandić, Višeslav Popadić, Novica Nikolić, et al. Alcohol, inflammation, and microbiota in alcoholic liver disease. *International journal of molecular sciences*, 24(4):3735, 2023.

[26] James A Heslop, Cliff Rowe, Joanne Walsh, Rowena Sison-Young, Roz Jenkins, Laleh Kamalian, Richard Kia, David Hay, Robert P Jones, Hassan Z Malik, et al. Mechanistic evaluation of primary human hepatocyte culture using global proteomic analysis reveals a selective dedifferentiation profile. *Archives of toxicology*, 91:439–452, 2017.

[27] Siamon Gordon and Luisa Martinez-Pomares. Physiological roles of macrophages. *Pflügers Archiv-European Journal of Physiology*, 469(3):365–374, 2017.

[28] Ming-Jiang Xu, Zhou Zhou, Richard Parker, and Bin Gao. Targeting inflammation for the treatment of alcoholic liver disease. *Pharmacology & Therapeutics*, 180:77–89, 2017.

[29] Salvatore Sutti and Frank Tacke. Liver inflammation and regeneration in drug-induced liver injury: sex matters! *Clinical Science*, 132(5):609–613, 2018.

[30] Yang Liu, Ruyi Xu, Huiyao Gu, Enfan Zhang, Jianwei Qu, Wen Cao, Xi Huang, Haimeng Yan, Jingsong He, and Zhen Cai. Metabolic reprogramming in macrophage responses. *Biomarker Research*, 9:1–17, 2021.

[31] Gisa Tiegs and Andrea K Horst. Tnf in the liver: targeting a central player in inflammation. In *Seminars in immunopathology*, volume 44, pages 445–459. Springer, 2022.

[32] Yoon Mee Yang, So Yeon Kim, and Ekihiro Seki. Inflammation and liver cancer: molecular mechanisms and therapeutic targets. In *Seminars in liver disease*, volume 39, pages 026–042. Thieme Medical Publishers, 2019.

[33] Benjamin L Woolbright and Hartmut Jaeschke. The impact of sterile inflammation in acute liver injury. *Journal of clinical and translational research*, 3(1):170, 2017.

[34] Shabnam Shalapour, Xue-Jia Lin, Ingmar N Bastian, John Brain, Alastair D Burt, Alexander A Aksenov, Alison F Vrbanac, Weihua Li, Andres Perkins, Takaji Matsutani, et al. Inflammation-induced iga+ cells dismantle anti-liver cancer immunity. *Nature*, 551(7680):340–345, 2017.

[35] Julia Bruner, Kyle Adams, Skylar Grey, Mahya Aghaee, Sergio Duarte, Ali Zarrinpar, and Helen Moore. Understanding immune dynamics in liver transplant through mathematical modeling, 2024.

[36] Thibaut Duparc, Hubert Plovier, Vannina G Marrachelli, Matthias Van Hul, Ahmed Essaghir, Marcus Ståhlman, Sébastien Matamoros, Lucie Geurts, Mercedes M Pardo-Tendero, Céline Druart, et al. Hepatocyte myd88 affects bile acids, gut microbiota and metabolome contributing to regulate glucose and lipid metabolism. *Gut*, 66(4):620–632, 2017.

[37] Christoph Welsch, Mira Efinger, Michael von Wagner, Eva Herrmann, Stefan Zeuzem, Tania M Welzel, and Christian M Lange. Ongoing liver inflammation in patients with chronic hepatitis c and sustained virological response. *PloS one*, 12(2):e0171755, 2017.

[38] Brent A Neuschwander-Tetri. Non-alcoholic fatty liver disease. *BMC medicine*, 15:1–6, 2017.

[39] Arun J Sanyal. Past, present and future perspectives in nonalcoholic fatty liver disease. *Nature reviews Gastroenterology & hepatology*, 16(6):377–386, 2019.

[40] Hossein Sendi, Ivy Mead, Meimei Wan, Marjan Mehrab-Mohseni, Kenneth Koch, Anthony Atala, Herbert L Bonkovsky, and Colin E Bishop. mir-122 inhibition in a human liver organoid model leads to liver inflammation, necrosis, steatofibrosis and dysregulated insulin signaling. *PloS one*, 13(7):e0200847, 2018.

Disclaimer:

SurveyX is an AI-powered system designed to automate the generation of surveys. While it aims to produce high-quality, coherent, and comprehensive surveys with accurate citations, the final output is derived from the AI's synthesis of pre-processed materials, which may contain limitations or inaccuracies. As such, the generated content should not be used for academic publication or formal submissions and must be independently reviewed and verified. The developers of SurveyX do not assume responsibility for any errors or consequences arising from the use of the generated surveys.



Figure 2: This figure illustrates the core concepts and definitions related to liver disease and macrophage polarization, highlighting the significance of NAFLD and the roles of macrophages in liver pathology. The diagram categorizes key terms, macrophage origins, functions, and polarization dynamics, emphasizing their impact on disease progression and potential therapeutic strategies.



Figure 3: This figure illustrates the key roles of macrophages in tissue homeostasis and immune regulation, their polarization into M1 and M2 states, and the implications for liver diseases such as NAFLD and ALD.



Figure 4: This figure illustrates the hierarchical structure of macrophage polarization and function, focusing on their roles in tissue homeostasis and immune modulation, the distinction between M1 and M2 macrophage phenotypes, and their impact on liver diseases such as NAFLD and ALD.



Figure 5: This figure illustrates the hierarchical structure of key concepts related to inflammation and fibrosis in liver disease, highlighting cellular mechanisms, molecular pathways, and therapeutic insights.



Figure 6: This figure illustrates the therapeutic targets and strategies for NAFLD and NASH, focusing on hepatocyte-macrophage interactions, key signaling pathways, and emerging therapies.